New Delhi [India], June 15 (ANI): The subject expert committee meeting that was scheduled today to discuss Serum Institute of India's (SII) indigenously developed Quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer, has recommended regular market authorisation for above 9 to 26-year-old male and female, according to sources.
\
\
